- Entasis Therapeutics Holdings Inc ETTX stock is up sharply after the journal Nature published an article on the potential of its preclinical candidate ETX0462, which could become the first of a new class of antibiotics.
- ETX0462 is under development for multidrug-resistant Gram-negative and biothreat infections.
- The manuscript details the discovery of ETX0462, highlighting concurrent optimization of biochemical potency and drug penetration into the bacterial cells to identify structural elements critical for antimicrobial activity.
- ETX0462 can permeate bacterial cells through multiple porins, and inhibition of multiple penicillin-binding proteins enzyme subtypes results in a low likelihood of antibiotic resistance.
- Price Action: ETTX shares are up 10.60% at $3.03 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechLong IdeasNewsPenny StocksHealth CareMoversTrading IdeasGeneralantibioticsBriefswhy it's moving
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
